GPCR · Structure Therapeutics Inc.
← all insidersPharmaceutical Preparations · Listed on Nasdaq
Open-market insider flow over 30d · 90d · 180d · 365d · filter in table · CSV · JSON
Open-market trades13
Distinct insiders2
Bought$0
Sold$2.35M
Net flow$-2.35M
Recent filings
How to read this
- Filed
- Date the Form 4 was filed with the SEC. Insiders must file within 2 business days of the trade.
- Ticker
- The issuer's stock symbol. Select it to open that company's insider-activity page.
- Issuer
- The company whose shares were traded.
- Sector
- The issuer's industry (SEC SIC classification). Select a value to filter to that sector.
- Insider
- The reporting person: an officer, director, or 10% owner. Select a name to see all of their trades.
- Role
- The insider's relationship to the company: director, officer, or 10% owner.
- Code
- SEC transaction code describing the kind of transaction. Full official definitions are under “Transaction codes” below. A dot marks an open-market trade (P/S), the highest-conviction signal.
- Side
- Direction of the trade, from the filing's Acquired (A) ▲ / Disposed of (D) ▼ field: a buy or a sell.
- 10b5-1
- Trade made under a pre-arranged Rule 10b5-1 plan: scheduled in advance, not a discretionary decision (generally lower signal).
- Shares
- Number of shares in this transaction.
- Price
- Reported price per share. Blank for grants, gifts, and other trades with no stated price.
- Value
- Transaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ for their impact).
- Owned after
- Form 4 column “Amount of Securities Beneficially Owned Following Reported Transaction(s)”: shares the insider held (directly or indirectly) immediately after this trade.
- Own Δ
- How much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing.
- Co. Δ
- Change in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake. Based on the latest reported shares outstanding; blank when unavailable.
- D/I
- Form 4 column “Ownership Form: Direct (D) or Indirect (I)”. Indirect holdings (for example, through a trust, fund, or family member) are detailed in the filing's “Nature of Indirect Beneficial Ownership.”
- Lag
- Days from the trade date to the filing date (Form 4 is due within 2 business days).
Transaction codes
Verbatim from the SEC's General Instructions for Forms 3, 4 and 5.
- P
- Open market or private purchase of non-derivative or derivative security
- S
- Open market or private sale of non-derivative or derivative security
- A
- Grant, award or other acquisition pursuant to Rule 16b-3(d)
- D
- Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
- F
- Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
- M
- Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
- G
- Bona fide gift
- C
- Conversion of derivative security
- X
- Exercise of in-the-money or at-the-money derivative security
- J
- Other acquisition or disposition (describe transaction)
| Filed ↓Date the Form 4 was filed with the SEC (due within 2 business days of the trade). | Insider | Role | CodeSEC transaction code describing the kind of transaction. See “How to read this” above for the official SEC definition of each code. The dot marks an open-market trade (P/S). | SideDirection of the trade: a buy (acquired ▲) or a sell (disposed ▼). | Shares | PriceReported price per share. Blank for trades with no stated price. | ValueTransaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ). | Owned afterShares the insider held (directly or indirectly) immediately after this trade. | Own ΔHow much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing. | Co. ΔChange in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake in the company. Based on the latest reported shares outstanding; blank when unavailable. | Link to SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-02 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 100→ 100 Ordinary Shares | $47.83 | $4.8K | 0 | — | — | filing |
| 2026-09-02 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 4,539→ 4,539 Ordinary Shares | $47.20 | $214.3K | 100 | — | — | filing |
| 2026-09-02 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 1,300→ 1,300 Ordinary Shares | $45.86 | $59.6K | 4,639 | — | — | filing |
| 2026-09-02 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | C | ▲ buy10b5-1 | 5,939→ 5,939 Ordinary Shares | — | — | 5,939 | — | — | filing |
| 2026-09-02 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | M | ▼ sell10b5-1 | 17,817→ 17,817 Ordinary Shares | — | — | 125,081 | — | — | filing |
| 2026-09-02 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | C | ▼ sell10b5-1 | 17,8170 | — | — | 228,960 | −7% | −<0.01% (now 0.11%) | filing |
| 2026-09-02 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | M | ▲ buy10b5-1 | 17,8170 | $0.34 | $6.1K | 246,777 | +8% | +<0.01% (now 0.12%) | filing |
| 2026-08-19 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 400→ 1,200 Ordinary Shares | $55.05 | $22.0K | 0 | — | — | filing |
| 2026-08-19 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 519→ 1,557 Ordinary Shares | $54.20 | $28.1K | 400 | — | — | filing |
| 2026-08-19 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 3,020→ 9,060 Ordinary Shares | $53.13 | $160.5K | 919 | — | — | filing |
| 2026-08-19 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | C | ▲ buy10b5-1 | 3,939→ 11,817 Ordinary Shares | — | — | 3,939 | — | — | filing |
| 2026-08-19 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | M | ▼ sell10b5-1 | 11,817→ 11,817 Ordinary Shares | — | — | 142,898 | — | — | filing |
| 2026-08-19 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | C | ▼ sell10b5-1 | 11,8170 | — | — | 228,960 | −5% | −<0.01% (now 0.11%) | filing |
| 2026-08-19 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | M | ▲ buy10b5-1 | 11,8170 | $0.34 | $4.0K | 240,777 | +5% | +<0.01% (now 0.11%) | filing |
| 2026-08-07 | Berrios John Joseph | Officer (Chief Commercial Officer) | A | ▲ buy | 174,612→ 174,612 Ordinary Shares | — | — | 174,612 | — | — | filing |
| 2026-08-07 | Berrios John Joseph | Officer (Chief Commercial Officer) | A | ▲ buy | 140,7660 | — | — | 140,766 | new | +0.07% (now 0.07%) | filing |
| 2026-08-05 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 839→ 2,517 Ordinary Shares | $50.03 | $42.0K | 0 | — | — | filing |
| 2026-08-05 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 3,100→ 9,300 Ordinary Shares | $49.29 | $152.8K | 839 | — | — | filing |
| 2026-08-05 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | C | ▲ buy10b5-1 | 3,939→ 11,817 Ordinary Shares | — | — | 3,939 | — | — | filing |
| 2026-08-05 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | M | ▼ sell10b5-1 | 11,817→ 11,817 Ordinary Shares | — | — | 154,715 | — | — | filing |
| 2026-08-05 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | C | ▼ sell10b5-1 | 11,8170 | — | — | 228,960 | −5% | −<0.01% (now 0.11%) | filing |
| 2026-08-05 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | M | ▲ buy10b5-1 | 11,8170 | $0.34 | $4.0K | 240,777 | +5% | +<0.01% (now 0.11%) | filing |
| 2026-07-24 | FMR LLC | 10% owner, See Remark 1 | S | ▼ sell | 16,085→ 48,255 Ordinary Shares | $50.07 | $805.4K | 16,086 | — | — | filing |
| 2026-07-24 | FMR LLC | 10% owner, See Remark 1 | S | ▼ sell | 1,367→ 4,101 Ordinary Shares | $50.07 | $68.4K | 1,369 | — | — | filing |
| 2026-07-15 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 1,600→ 4,800 Ordinary Shares | $51.71 | $82.7K | 0 | — | — | filing |
| 2026-07-15 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 6,278→ 18,834 Ordinary Shares | $50.80 | $318.9K | 1,600 | — | — | filing |
| 2026-07-15 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | C | ▲ buy10b5-1 | 7,878→ 23,634 Ordinary Shares | — | — | 7,878 | — | — | filing |
| 2026-07-15 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | M | ▼ sell10b5-1 | 23,634→ 23,634 Ordinary Shares | — | — | 166,532 | — | — | filing |
| 2026-07-15 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | C | ▼ sell10b5-1 | 23,6340 | — | — | 228,960 | −9% | −0.01% (now 0.11%) | filing |
| 2026-07-15 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | M | ▲ buy10b5-1 | 23,6340 | $0.34 | $8.0K | 252,594 | +10% | +0.01% (now 0.12%) | filing |
| 2026-06-29 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | S | ▼ sell10b5-1 | 7,878→ 23,634 Ordinary Shares | $49.08 | $386.6K | 0 | — | — | filing |
| 2026-06-29 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | C | ▲ buy10b5-1 | 7,878→ 23,634 Ordinary Shares | — | — | 7,878 | — | — | filing |
| 2026-06-29 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | M | ▼ sell10b5-1 | 23,634→ 23,634 Ordinary Shares | — | — | 190,166 | — | — | filing |
| 2026-06-29 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | C | ▼ sell10b5-1 | 23,6340 | — | — | 228,960 | −9% | −0.01% (now 0.11%) | filing |
| 2026-06-29 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | M | ▲ buy10b5-1 | 23,6340 | $0.34 | $8.0K | 252,594 | +10% | +0.01% (now 0.12%) | filing |
| 2026-06-18 | Waldstreicher Joanne | Director | A | ▲ buy | 39,453→ 39,453 Ordinary Shares | — | — | 39,453 | — | — | filing |
| 2026-06-18 | TETLOW SHARON | Director | A | ▲ buy | 39,453→ 39,453 Ordinary Shares | — | — | 39,453 | — | — | filing |
| 2026-06-18 | WELCH DANIEL G | Director | A | ▲ buy | 39,453→ 39,453 Ordinary Shares | — | — | 39,453 | — | — | filing |
| 2026-06-18 | Russell Angus C. | Director | A | ▲ buy | 39,453→ 39,453 Ordinary Shares | — | — | 39,453 | — | — | filing |
| 2026-06-18 | LOVE TED W | Director | A | ▲ buy | 39,453→ 39,453 Ordinary Shares | — | — | 39,453 | — | — | filing |
| 2026-06-18 | DOBMEIER ERIC | Director | A | ▲ buy | 39,453→ 39,453 Ordinary Shares | — | — | 39,453 | — | — | filing |
| 2026-04-23 | Lang Matthew | Officer (COO & GC) | A | ▲ buy | 223,776→ 223,776 Ordinary Shares | — | — | 223,776 | — | — | filing |
| 2026-04-23 | Lang Matthew | Officer (COO & GC) | A | ▲ buy | 184,6140 | — | — | 184,614 | new | +0.09% (now 0.09%) | filing |
| 2026-04-16 | FMR LLC | 10% owner, See Remark 1 | S | ▼ sell | 16,085→ 48,255 Ordinary Shares | $55.07 | $885.8K | 32,171 | — | — | filing |
| 2026-04-16 | FMR LLC | 10% owner, See Remark 1 | S | ▼ sell | 1,367→ 4,101 Ordinary Shares | $55.07 | $75.3K | 2,736 | — | — | filing |
| 2026-03-23 | Yoon Jun | Officer (CHIEF FINANCIAL OFFICER) | A | ▲ buy | 128,892→ 128,892 Ordinary Shares | — | — | 128,892 | — | — | filing |
| 2026-03-23 | Yoon Jun | Officer (CHIEF FINANCIAL OFFICER) | A | ▲ buy | 104,0850 | — | — | 1,401,656 | +8% | +0.05% (now 0.66%) | filing |
| 2026-03-23 | Stevens Raymond C | Director, Officer (CHIEF EXECUTIVE OFFICER) | A | ▲ buy | 322,230→ 322,230 Ordinary Shares | — | — | 322,230 | — | — | filing |
| 2026-03-23 | Stevens Raymond C | Director, Officer (CHIEF EXECUTIVE OFFICER) | A | ▲ buy | 260,2170 | — | — | 1,401,593 | +23% | +0.12% (now 0.66%) | filing |
| 2026-03-23 | Ma Yingli | Officer (CHIEF TECHNOLOGY OFFICER) | A | ▲ buy | 40,278→ 40,278 Ordinary Shares | — | — | 40,278 | — | — | filing |
| 2026-03-23 | Ma Yingli | Officer (CHIEF TECHNOLOGY OFFICER) | A | ▲ buy | 32,5260 | — | — | 139,917 | +30% | +0.02% (now 0.07%) | filing |
| 2026-03-23 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | A | ▲ buy | 53,703→ 53,703 Ordinary Shares | — | — | 53,703 | — | — | filing |
| 2026-03-23 | Lin Xichen | Officer (CHIEF SCIENTIFIC OFFICER) | A | ▲ buy | 43,3680 | — | — | 228,960 | +23% | +0.02% (now 0.11%) | filing |
| 2026-03-23 | Hall Ashley | Officer (Chief Development Officer) | A | ▲ buy | 59,073→ 59,073 Ordinary Shares | — | — | 59,073 | — | — | filing |
| 2026-03-23 | Hall Ashley | Officer (Chief Development Officer) | A | ▲ buy | 47,7060 | — | — | 155,187 | +44% | +0.02% (now 0.07%) | filing |
| 2026-03-23 | Coll Crespo Blas | Officer (CHIEF MEDICAL OFFICER) | A | ▲ buy | 93,984→ 93,984 Ordinary Shares | — | — | 93,984 | — | — | filing |
| 2026-03-23 | Coll Crespo Blas | Officer (CHIEF MEDICAL OFFICER) | A | ▲ buy | 75,8970 | — | — | 280,878 | +37% | +0.04% (now 0.13%) | filing |
Up to 200 most recent filings · select a heading to sort, or open “How to read this” above for definitions · this company on SEC EDGAR.